期刊文献+

第五代头孢菌素类药物的药理学特点及临床应用 被引量:5

Research progress of the fifth generation cephalosporins
原文传递
导出
摘要 目的:总结第五代头孢菌素类药物的药理学特点及临床应用。方法选取已经上市的两种第五代头孢菌素类药物(头孢洛林、头孢吡普)作为研究对象,对其药理学特点、药效学、耐药性与不良反应以及临床应用等方面进行综述。结果与其他头孢菌素类药物比较,第五代头孢菌素类药物的抗菌谱更广且无严重不良反应,特别是对酶的稳定性较好,耐药率低,对 MRSA 活性较高,目前作为皮肤感染、软组织感染等疾病的批准临床用药。结论第五代头孢菌素类药物具有抗菌谱广、抗菌效力强、对酶的稳定性良好及安全性高等优势,应用前景较好。 Objective To summary the pharmacological characteristics of the fifth generation cephalosporins and clinical application. Methods Two kinds of the fifth generation cephalosporins(cefotaximeLorraine,ceftobiprole)were already marketed were selected as the research objects. Pharmacology and clinical application of them including the phar-macodynamics,drug resistance and adverse reaction were analyzed. Results Compared with other cephalosporins,broader antibacterial spectrum and no serious adverse reactions of the fifth generation cephalosporins,especially on enzyme stability was good,low rate of resistance,the higher MRSA activity. At present,it is used for the infection of the skin and soft tis-sue infection as the clinical approved medication. Conclusions The fifth generation of cephalosporins has broad antibacte-rial spectrum,strong antibacterial effect on enzyme stability,good and high security and good application prospect.
出处 《中国实用医刊》 2016年第10期125-126,共2页 Chinese Journal of Practical Medicine
关键词 第五代头孢菌素类药物 药理学 临床应用 Fifth generation cephalosporins Pharmacology Clinical application
  • 相关文献

参考文献8

二级参考文献29

  • 1张庆,庆格乐,许军.141例呼吸科病历抗菌药物的调查与分析[J].中国医院用药评价与分析,2004,4(5):281-284. 被引量:2
  • 2IKEDA Y, BAN J, ISHIKAWA T, et al. Stability and stabiliza tion studies of TAK-599 (Ceftaroline Fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825 [ J]. Chem Pharm Bull (Tokyo) , 2008, 56(10) :1406 - 1411. 被引量:1
  • 3FDA. Approves teflaro for bacterial infectlons[EB/OL]. [2011 - 04 - 18]. http://www, fda. gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm231594, htm. 被引量:1
  • 4STEED ME, RYBAK MJ. Ceftaroline: a new eephalosporin with activity against resistant gram-positive pathogens[ J ]. Pharmaco- therapy, 2010, 30(4) :375 -389. 被引量:1
  • 5SARAVOLATZ LD, STEIN GE, JOHNSON LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus [ J]. Clin Infect Dis, 2011, 52 (9) : 1156 - 1163. 被引量:1
  • 6LIM L, SUTTON E, BROWN J. Ceftaroline: a new broad-spectrum cephalosporin [J]. Am J Health Syst Pharm, 2011, 68 (6) :491 -498. 被引量:1
  • 7KAUSHIK D, RATHI S, JAIN A. Ceftaroline: a comprehensive update [ J ]. Int J Antimicrob Agents, 2011, 37 (5) : 389 - 395. 被引量:1
  • 8SARAVOLATZ L, PAWLAK J, JOHNSON L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycinnonsusceptible Staphylococcus aureus isolates[ J]. Antimicrob Agents Chemother, 2010, 54(7):3027- 3030. 被引量:1
  • 9MORRISSEY I, GE Y, JANES R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia [ J ].Int J Antimicrob Agents, 2009, 33(6) :515 -519. 被引量:1
  • 10VIDAILLAC C, LEONARD SN, RYBAK MJ. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus ( HAMRSA) isolates[J].Int JAntimicrob Agents, 2010, 35 (6): 527 -530. 被引量:1

共引文献6

同被引文献26

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部